Abstract OT1-20-02: Intralesional injection of anti-PD-1 (pembrolizumab) and OX40L/IL-23/IL-36 mRNAs (mRNA-2752) results in regression of DCIS characterized by lymphocytic infiltrates

作者
Laura J. Esserman,Alexa Glencer,Kirithiga Ramalingam,Christopher J. Schwartz,Alexander D. Borowsky,Gillian L. Hirst,Rachel Woody,Nicole J. Schindler,Nola M. Hylton,Michael J. Campbell
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (5_Supplement): OT1-20
标识
DOI:10.1158/1538-7445.sabcs22-ot1-20-02
摘要

Abstract Background: High-grade DCIS with immune infiltrates may represent lesions that are able to be kept in check by the immune system, but still are at risk for progression to invasive disease. We and others have demonstrated that the presence of T cells, and in particular the spatial proximity of CD8+/PD-1+ T cells and PD-L1+ cells predicts response to chemotherapy and PD-1 inhibitors in the setting of invasive triple negative breast cancer. DCIS with high-risk features (e.g. large, palpable, high grade, HR-, or HER2+) often have T cell infiltrates. We hypothesized that it might be possible to potentiate the immune response in high-risk DCIS with immune checkpoint blockade. Since mortality for DCIS is extremely low, we proposed an intralesional pembrolizumab (pembro) treatment approach to avoid systemic adverse effects. In a phase 1 dose escalation study of single agent pembro we found 2 doses of 8 mg, administered intralesionally 2-3 wks apart, was tolerable, induced immunological changes within the DCIS lesions, but had little clinical benefit. Herein, we expanded the number of injections to 4 and also tested a combination with mRNA-2752 (Moderna), an mRNA-based therapeutic encoding a T cell co-stimulator OX40L, and pro-inflammatory cytokines IL-23 and IL-36 gamma, to determine if we could find a dose that was both tolerable and elicited anti-tumor responses. Methods Women eligible for this study had DCIS with at least 2 of the following high-risk features: age< 45; high grade, extensive comedonecrosis; palpable mass; hormone receptor negative [HR-]; HER2+; size >5 cm, or microinvasion. A dose expansion cohort was performed using 4 doses of 8 mg pembro, 2-3 wks apart (n=5). We then combined pembro with mRNA-2752 (n=8 cases), initially at 8 and 4 mg, respectively. Dose reductions were implemented based on AEs. Patients received an MRI before and after 2 injections, spaced 2-3 wks apart. A total of 4 injections were allowed. Core biopsy or surgery was conducted after the last MRI. Results We observed an increase in T cell density in the dose expansion cohort (pembro only), except when there was a paucity of T cells in the pre-treatment biopsy. However, only 1 patient in this cohort demonstrated a reduction in lesion size (clinically and on MRI). As of 22SEP22, 8 patients have received the combination of pembro and mRNA-2752; 7 are evaluable. Two patients with minimal T cell infiltrates at baseline (both HR+) failed to respond, based on imaging or pathology. 4/5 patients with moderate to high T cell infiltrates at baseline had partial (2) or complete responses (2) based on imaging (surgery pending), one of whom had absence of DCIS on post-therapy core biopsy and a clear MRI 4 months later. Correlative studies (immune cell densities, spatial proximities) will be presented at the meeting along with complete data (including post-treatment pathology) on the first 8 patients. Side effects were independent of response and included Gr1/2 fever, myalgias, and fatigue starting within 12 hours of injection (3-4 days), enlargement of regional nodes by day 2, and Gr 1/2 erythema and induration of the breast starting at 4 days and lasting 4-20 days. Earlier onset and persistence of symptoms with subsequent exposure required dose reductions for the majority of patients to maintain tolerability (avoid fevers over 39.4°C, intense erythema and swelling of the breast lasting > 4 days). No AEs were higher than grade 2. Conclusion: The combination of intralesional pembro and mRNA-2752 demonstrated modulation of the tumor immune microenvironment and robust antitumor activity in high-risk DCIS (typically HR- or HER2+) with existing T cell infiltrates. This is an ongoing study; the optimal Phase 2 dose for the combination will be based on the totality of evolving safety and translational data. Citation Format: Laura J. Esserman, Alexa Glencer, Kirithiga Ramalingam, Christopher J. Schwartz, Alexander Borowsky, Gillian L. Hirst, Rachel Woody, Nicole Schindler, Nola M. Hylton, Michael Campbell. Intralesional injection of anti-PD-1 (pembrolizumab) and OX40L/IL-23/IL-36 mRNAs (mRNA-2752) results in regression of DCIS characterized by lymphocytic infiltrates [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT1-20-02.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
懒羊羊完成签到 ,获得积分10
3秒前
川川贝贝宝完成签到 ,获得积分10
4秒前
kiterunner完成签到,获得积分10
5秒前
圆1223完成签到 ,获得积分10
6秒前
荣幸完成签到 ,获得积分10
6秒前
小金鱼8569完成签到,获得积分10
10秒前
随心所欲完成签到 ,获得积分0
10秒前
苗条的白梅完成签到,获得积分10
10秒前
xybjt完成签到 ,获得积分10
12秒前
大呲花完成签到,获得积分10
16秒前
成就苞络完成签到,获得积分10
18秒前
w0r1d完成签到 ,获得积分10
18秒前
xiaojinyu195完成签到,获得积分10
20秒前
xiaojinyu131完成签到,获得积分10
30秒前
Connie425完成签到 ,获得积分10
30秒前
alixy完成签到,获得积分10
30秒前
萌萌2完成签到,获得积分10
39秒前
爱沉淀的太阳花完成签到,获得积分10
40秒前
42秒前
xiaoxiao完成签到 ,获得积分10
44秒前
LingMg完成签到 ,获得积分10
44秒前
丰富的澜完成签到 ,获得积分10
46秒前
文文完成签到 ,获得积分10
48秒前
Brave发布了新的文献求助10
48秒前
妙海完成签到,获得积分10
48秒前
萌萌1完成签到,获得积分10
49秒前
灵巧的谷南完成签到 ,获得积分10
50秒前
小鱼崽完成签到 ,获得积分10
51秒前
666666神花露水完成签到 ,获得积分10
52秒前
CipherSage的应助被豆豆采纳,获得10
52秒前
幸福的映容完成签到 ,获得积分10
54秒前
馨妈完成签到 ,获得积分10
54秒前
JinwenShi完成签到,获得积分10
56秒前
欢喜语柳完成签到 ,获得积分10
57秒前
魔幻的晓灵完成签到,获得积分10
1分钟前
hxs606完成签到 ,获得积分10
1分钟前
温暖的寻雪完成签到 ,获得积分10
1分钟前
科研通AI6.2的应助被孙丽菲采纳,获得10
1分钟前
凝望星空完成签到,获得积分10
1分钟前
科研助理完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012